Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | ITK | Q08881 | 9/20 | 0.44 |
| ▸ | BTK | Q06187 | 5/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22676067 | 1.00 | JAK2 (0.45) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL30303449 | 0.94 | EGFR (0.48) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL22678103 | 0.94 | EGFR (0.48) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL22676418 | 0.93 | EGFR (0.47) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL22676419 | 0.89 | EGFR (0.45) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL30303856 | 0.89 | EGFR (0.45) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL22676085 | 0.89 | EGFR (0.45) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL22676335 | 0.88 | EGFR (0.43) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL22677235 | 0.87 | EGFR (0.46) | JAK2JAK1JAK3EGFRITK | |
| SCHEMBL30303516 | 0.87 | EGFR (0.46) | JAK2JAK1JAK3EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3968999-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | JAK2 26/4885JAK1 60/4885JAK3 78/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | JAK2 26/4885JAK1 60/4885JAK3 78/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | JAK2 26/4885JAK1 60/4885JAK3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.